Alisoltani, Arghavan
Simons, Lacy M.
Agnes, Maria Francesca Reyes
Heald-Sargent, Taylor A.
Muller, William J.
Kociolek, Larry K.
Hultquist, Judd F.
Lorenzo-Redondo, Ramon
Ozer, Egon A.
Funding for this research was provided by:
Dixon Translational Research Grant made possible by the generous support of the Dixon Family Foundation
National Center for Advancing Translational Sciences (UL1 TR001422, UL1 TR002389)
Northwestern University Cancer Center (P30 CA060553)
NIH-supported Third Coast CFAR (P30 AI117943)
National Institutes of Health (U19 AI171110, U19 AI135964)
Walder Foundation Foundation’s Chicago Coronavirus Assessment Network (Chicago CAN) Initiative
Article History
Received: 30 June 2023
Accepted: 18 September 2023
First Online: 27 October 2023
Declarations
:
: J.F.H. has received research support, paid to Northwestern University, from Gilead Sciences and is a paid consultant for Merck. W.J.M. has received research support, paid to Lurie Children’s, from Ansun Biopharma, Astellas Pharma, AstraZeneca, Eli Lilly and Company, Enanta Pharmaceuticals, F. Hoffmann-La Roche, Gilead Sciences, Janssen Biotech, Karius, Inc., Melinta Therapeutics, Inc., Merck, Moderna, Nabriva Therapeutics, plc, Paratek Pharmaceuticals, Inc., Pfizer, and Tetraphase Pharmaceuticals, Inc. and has been a paid consultant for AstraZeneca, DiaSorin Molecular, Invivyd, and Sanofi Pasteur. All other authors declare no conflicts of interest.
: This study was approved by the Ann & Robert H. Lurie Children’s Hospital of Chicago Institutional Review Board (IRB 2020–3792).
: Not applicable.